Waiv
Owkin spinout developing AI models that analyze routine histopathology slides to detect and characterize cancer, bringing precision oncology diagnostics to standard clinical workflows.
Overview
Waiv is a Paris-based spinout from Owkin, a leading AI biotech company, focused exclusively on developing AI models that read cancer from routine histopathology slides. By applying deep learning to standard tissue samples already collected during clinical care, Waiv enables earlier and more accurate cancer detection without requiring expensive specialized tests. The company's AI analyzes cellular patterns, tissue architecture, and biomarker expression from digitized pathology slides, providing oncologists with quantitative insights that complement traditional microscopic examination. Founded in 2025, Waiv bridges the gap between advanced AI research and clinical utility, aiming to make precision oncology diagnostics accessible at scale across hospitals and pathology labs worldwide.
Funding History
Owkin spinout Waiv raises $33M for AI that reads cancer from routine slides
Frequently Asked Questions
- How much funding does AI Funding track for Waiv?
- AI Funding tracks $33M for Waiv across 1 funding round in this database.
- Who are Waiv's investors?
- Waiv's investors include OTB Ventures, Alpha Intelligence Capital, Serena Data Ventures, Karista, SistaFund.
- What does Waiv do?
- Waiv is a Paris-based spinout from Owkin, a leading AI biotech company, focused exclusively on developing AI models that read cancer from routine histopathology slides. By applying deep learning to standard tissue samples already collected during clinical care, Waiv enables earlier and more accurate cancer detection without requiring expensive specialized tests. The company's AI analyzes cellular patterns, tissue architecture, and biomarker expression from digitized pathology slides, providing oncologists with quantitative insights that complement traditional microscopic examination. Founded in 2025, Waiv bridges the gap between advanced AI research and clinical utility, aiming to make precision oncology diagnostics accessible at scale across hospitals and pathology labs worldwide.
- When was Waiv founded?
- Waiv was founded in 2025 and is headquartered in Paris, France.
- Where is Waiv headquartered?
- Waiv is headquartered in Paris, France.
Investors
Related Insights
A data-driven analysis of AI funding across all 17 sectors — from Foundation Models to AI Healthcare — with sector totals, deal counts, top companies, and investment trends for 2026.
A comprehensive, data-driven analysis of AI venture funding in Q1 2026. $25.9 billion raised across 94 deals, with 14 mega-rounds capturing 79.8% of total capital. Europe breaks out with $6.65B, and billion-dollar seed rounds arrive for the first time.
A deep comparison of Science Corp.'s neurotech-driven brain-computer interfaces and Nscale's AI cloud infrastructure, examining how $230M and $2B in recent funding fuel fundamentally different visions of artificial intelligence.